Seven states have legalized physician-assisted death (PAD) for competent, terminally ill individuals; these criteria exclude persons with dementia (PWD). However, there is ethical and policy discussion around expanding access to PAD to people with Alzheimer disease (AD).1,2 Here, we present attitudes toward PAD of cognitively normal individuals enrolled in a clinical trial that required them to learn whether they have elevated amyloid-β, a biomarker that increases risk for cognitive decline owing to AD.3
Largent EA, Terrasse M, Harkins K, Sisti DA, Sankar P, Karlawish J. Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker. JAMA Neurol. Published online April 29, 201976(7):864–866. doi:10.1001/jamaneurol.2019.0797
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: